Akorn (AKRX) Guides FY13 adj.-EPS Below Views, Revs In-Line; Reaffirms FY12

January 17, 2013 2:33 PM EST
Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, today provided full year 2013 financial guidance. The Company’s guidance excludes the impact from any products for which the Company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2012 conference call.

Total revs of $325 million to $335 million. The Street is at $330.7 million.

SG&A expenses of $51 million to $54 million.

Adjusted net income per share of 57 cents to 61 cents. The Street is at 66 cents.

CapEx of about $25 million.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Guidance, Hot Guidance

Add Your Comment